Form 8-K December 01, 2005

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

# PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 1, 2005

## CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of Incorporation)	<b>0-30379</b> (Commission File Number)	88-0425691 (IRS Employer Identification Number)
-	3661	
	Horseblock	
	Road	
	Medford, NY	
	11763	
	(Address of	
	principal	
	executive	
	offices)	
	631-924-1135	
	(Registrant's	
	Telephone	
	Number)	

### N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

# Edgar Filing: CHEMBIO DIAGNOSTICS, INC. - Form 8-K

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### ITEM 7.01. Regulation FD Disclosures.

99.1 On December 1, 2005 the Registrant issued the press release titled "On World Aids Day Chembio Updates Its Progress In Serving Global Need For Rapid HIV Testing" included herein as Exhibit 99.1.

#### ITEM 9.01. Financial Statements and Exhibits

- (c) Exhibits.
- 99.2 <u>Press Release titled "On World Aids Day Chembio Updates Its Progress In Serving Global Need For Rapid HIV Testing" issued November 7, 2005</u>.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 1, 2005 Chembio Diagnostics, Inc.

By: <u>/s/ Lawrence A. Siebert</u> Lawrence A. Siebert Chief Executive Officer